Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021738 | 0.91 | MDM2 (0.56) | MDM2KMT2ATLR2ALBMDM4 | |
| SCHEMBL31758278 | 0.90 | ALB (0.62) | MDM2KMT2ATLR2ALB | |
| SCHEMBL24193189 | 0.86 | MDM2 (0.55) | MDM2KMT2ATLR2ALB | |
| SCHEMBL21963412 | 0.86 | MDM2 (0.55) | MDM2KMT2ATLR2ALB | |
| SCHEMBL260631 | 0.85 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL178698 | 0.85 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL29359997 | 0.85 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL178733 | 0.85 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL29401258 | 0.85 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 | |
| SCHEMBL29528567 | 0.85 | KMT2A (0.66) | MDM2KMT2ATLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2020102348-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | DIMAGNO STEPHEN (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | ALB, TTR, ABCG2 | MDM2 1543/4885KMT2A 3069/4885TLR2 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.